UB Therapeutics
Updated: February 11, 2026
Founders: Dima Ghannam-Shahbari, Liora Sklair-Tavron, Ashraf Brik
Country: Israel | Funding: $415.4K (+)
Founded: 2023
Website: https://www.ub-therapeutics.com/
UB Therapeutics is developing new therapy for the treatment of multiple myeloma. It's candidate, proteasome degradation inhibitor, has shown great promise in early preclinical studies. It differs from other proteasome inhibitors in that it more directly targets the proteasome degradation pathway, potentially leading to increased efficacy in patients who have developed resistance to other FDA-approved proteasome inhibitors. The compound is a cyclic peptide with potential anticancer therapeutic activity, blocking the action of deubiquitinases and the proteasome, inducing apoptosis in vitro, and attenuating tumor growth in vivo. This distinct mechanism may have therapeutic advantages as it avoids the innate and acquired resistance associated with direct proteasome inhibitors.
Founded: 2023
Website: https://www.ub-therapeutics.com/
UB Therapeutics is developing new therapy for the treatment of multiple myeloma. It's candidate, proteasome degradation inhibitor, has shown great promise in early preclinical studies. It differs from other proteasome inhibitors in that it more directly targets the proteasome degradation pathway, potentially leading to increased efficacy in patients who have developed resistance to other FDA-approved proteasome inhibitors. The compound is a cyclic peptide with potential anticancer therapeutic activity, blocking the action of deubiquitinases and the proteasome, inducing apoptosis in vitro, and attenuating tumor growth in vivo. This distinct mechanism may have therapeutic advantages as it avoids the innate and acquired resistance associated with direct proteasome inhibitors.
